Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
87 hedge funds and large institutions have $93M invested in Navidea Biopharmaceuticals Inc. in 2014 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 12 closing their positions.
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
27% more capital invested
Capital invested by funds: $73.5M → $93M (+$19.5M)
7% more funds holding
Funds holding: 81 → 87 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
99% less call options, than puts
Call options by funds: $81K | Put options by funds: $12.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$826K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$344K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$158K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$133K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$6.25M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.34M |
| 3 |
PM
Platinum Management
New York
|
-$609K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$360K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$215K |
NAVB Hedge Fund Activity: Q4 2014 in Review
87 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2014, worth a combined $93M — up 27% from $73.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NAVB positions and 12 closed out — a net gain of 7 holders — while 20 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $826K. The largest seller was Nomura Holdings, exiting entirely with an estimated $6.25M sold.
- 87 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2014, up from 81 in Q3 2014.
- Funds reported $93M of Navidea Biopharmaceuticals Inc. stock for Q4 2014, up 27% quarter-over-quarter.
- 19 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2014 and 12 closed out, a net change of +7 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $826K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2014 was Nomura Holdings, an estimated $6.25M sold.
Based on aggregated 13F filings for Q4 2014.